Verona Completes Enrollment for ENHANCE-2 Trial of Ensifentrine
Verona Pharma has completed patient enrollment for ENHANCE-2, a Phase 3 clinical trial evaluating the safety and efficacy of ensifentrine, an inhalation therapy for chronic obstructive pulmonary disease (COPD). According to Verona, the trial exceeded its enrollment target of 800 participants, even amid the COVID-19 pandemic. Top-line data are…